Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage / 国际口腔科学杂志·英文版

Unrestrained inflammation is harmful to tissue repair and regeneration. Immune cell membrane-camouflaged nanoparticles have been proven to show promise as inflammation targets and multitargeted inflammation controls in the treatment of severe inflammation. Prevention and early intervention of inflammation can reduce the risk of irreversible tissue damage and loss of function, but no cell membrane-camouflaged nanotechnology has been reported to achieve stage-specific treatment in these conditions. In this study, we investigated the prophylactic and therapeutic efficacy of fibroblast membrane-camouflaged nanoparticles for topical treatment of early inflammation (early pulpitis as the model) with the help of in-depth bioinformatics and molecular biology investigations in vitro and in vivo. Nanoparticles have been proven to act as sentinels to detect and competitively neutralize invasive Escherichia coli lipopolysaccharide (E. coli LPS) with resident fibroblasts to effectively inhibit the activation of intricate signaling pathways. Moreover, nanoparticles can alleviate the secretion of multiple inflammatory cytokines to achieve multitargeted anti-inflammatory effects, attenuating inflammatory conditions in the early stage. Our work verified the feasibility of fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage, which widens the potential cell types for inflammation regulation.

A Clinical Study On Vindesine in the Interventional Treatment of Hepatic and Pulmonary Carcinomas / 介入放射学杂志

Purpose:To evaluate the efficacy and toxicity of vindercine(VDS)in the interven- tional treatment of hepatic and pulmonary carcinomas.Materials and Methods:30 cases of mid-ad- vanced hepatic and pulmonary carcinomas,among them,13 eases of primary hepatic carcinomas,7 cases of matastic hepatic carinomas and 10 cases of primary pulmonary carcinomas,were treated by selective arterial infusion chemotherapy.The combination chemotherapeutic regimens conpored of VDS together with 5-Fu,MMC,carboplatin or Vp16.Results:The response rate for all cases was 60%,for primary hepatic carcinomas 61.5%,for metastic hepatic carcinoma 42.9% and for primary pulmonary carcinoma 70%.Myelosuppession was the main toxicity and 70% patients had the gastrointertional reac- tions as nusea,vomiting etc.Conclusion:VSD is a more effective drug for pulmonary carcinoma,but for hepatic carcinoma,the efficacy of VDS was unmarkable from other drugs.